Literature DB >> 21603973

Expression profile and role of EphrinA1 ligand after spinal cord injury.

Luz C Arocho1, Johnny D Figueroa, Aranza I Torrado, José M Santiago, Ariel E Vera, Jorge D Miranda.   

Abstract

Spinal cord injury (SCI) triggers the re-expression of inhibitory molecules present in early stages of development, contributing to prevention of axonal regeneration. Upregulation of EphA receptor tyrosine kinases after injury suggest their involvement in the nervous system's response to damage. However, the expression profile of their ephrinA ligands after SCI is unclear. In this study, we determined the expression of ephrinA ligands after contusive SCI. Adult Sprague-Dawley female rats were injured using the MASCIS impactor device at the T10 vertebrae, and levels of ephrinA mRNA and protein determined at different time points. Identification of the cell phenotype expressing the ephrin ligand and colocalization with Eph receptors was performed with immunohistochemistry and confocal microscopy. Behavioral studies were made, after blocking ephrinA1 expression with antisense (AS) oligonucleotides, to assess hindlimb locomotor activity. Real-time PCR demonstrated basal mRNA levels of ephrin (A1, A2, A3, and A5) in the adult spinal cord. Interestingly, ephrinA1 was the only ligand whose mRNA levels were significantly altered after SCI. Although ephrinA1 mRNA levels increased after 2 weeks and remain elevated, we did not observe this pattern at the protein level as revealed by western blot analysis. Immunohistochemical studies showed ephrinA1 expression in reactive astrocytes, axons, and neurons and also their colocalization with EphA4 and A7 receptors. Behavioral studies revealed worsening of locomotor activity when ephrinA1 expression was reduced. This study suggests that ephrinA1 ligands play a role in the pathophysiology of SCI.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21603973      PMCID: PMC3216482          DOI: 10.1007/s10571-011-9705-2

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  64 in total

1.  Ephrins stimulate or inhibit neurite outgrowth and survival as a function of neuronal cell type.

Authors:  P P Gao; C H Sun; X F Zhou; E DiCicco-Bloom; R Zhou
Journal:  J Neurosci Res       Date:  2000-05-15       Impact factor: 4.164

2.  EphA receptors regulate growth cone dynamics through the novel guanine nucleotide exchange factor ephexin.

Authors:  S M Shamah; M Z Lin; J L Goldberg; S Estrach; M Sahin; L Hu; M Bazalakova; R L Neve; G Corfas; A Debant; M E Greenberg
Journal:  Cell       Date:  2001-04-20       Impact factor: 41.582

3.  Multiple ephrins regulate hippocampal neurite outgrowth.

Authors:  H Brownlee; P P Gao; J Frisen; C Dreyfus; R Zhou; I B Black
Journal:  J Comp Neurol       Date:  2000-09-18       Impact factor: 3.215

4.  Regulated cleavage of a contact-mediated axon repellent.

Authors:  M Hattori; M Osterfield; J G Flanagan
Journal:  Science       Date:  2000-08-25       Impact factor: 47.728

5.  Metalloproteinase increases in the injured rat spinal cord.

Authors:  R C de Castro; C L Burns; D J McAdoo; A M Romanic
Journal:  Neuroreport       Date:  2000-11-09       Impact factor: 1.837

Review 6.  Ephrins in reverse, park and drive.

Authors:  Chad A Cowan; Mark Henkemeyer
Journal:  Trends Cell Biol       Date:  2002-07       Impact factor: 20.808

7.  Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1.

Authors:  M S Chen; A B Huber; M E van der Haar; M Frank; L Schnell; A A Spillmann; F Christ; M E Schwab
Journal:  Nature       Date:  2000-01-27       Impact factor: 49.962

8.  Neurotrophic factors and receptors in the immature and adult spinal cord after mechanical injury or kainic acid.

Authors:  J Widenfalk; K Lundströmer; M Jubran; S Brene; L Olson
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

9.  Ephrin-B2 and EphB2 regulation of astrocyte-meningeal fibroblast interactions in response to spinal cord lesions in adult rats.

Authors:  Liza Q Bundesen; Tracy Aber Scheel; Barbara S Bregman; Lawrence F Kromer
Journal:  J Neurosci       Date:  2003-08-27       Impact factor: 6.167

10.  An adverse role for matrix metalloproteinase 12 after spinal cord injury in mice.

Authors:  Jennifer E A Wells; Tiffany K Rice; Robert K Nuttall; Dylan R Edwards; Hakima Zekki; Serge Rivest; V Wee Yong
Journal:  J Neurosci       Date:  2003-11-05       Impact factor: 6.167

View more
  5 in total

Review 1.  Therapeutic targeting of EPH receptors and their ligands.

Authors:  Andrew W Boyd; Perry F Bartlett; Martin Lackmann
Journal:  Nat Rev Drug Discov       Date:  2014-01       Impact factor: 84.694

2.  Acute delivery of EphA4-Fc improves functional recovery after contusive spinal cord injury in rats.

Authors:  Mark Damien Spanevello; Sophie Ines Tajouri; Cornel Mirciov; Nyoman Kurniawan; Martin John Pearse; Louis Jerry Fabri; Catherine Mary Owczarek; Matthew Philip Hardy; Rebecca Anne Bradford; Melanie Louise Ramunno; Ann Maree Turnley; Marc Jan Ruitenberg; Andrew Wallace Boyd; Perry Francis Bartlett
Journal:  J Neurotrauma       Date:  2013-06-15       Impact factor: 5.269

3.  Selected gene profiles of stressed NSC-34 cells and rat spinal cord following peripheral nerve reconstruction and minocycline treatment.

Authors:  Gerburg Keilhoff; Benjamin Lucas; Katja Uhde; Hisham Fansa
Journal:  Exp Ther Med       Date:  2016-03-02       Impact factor: 2.447

4.  Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist.

Authors:  Cassandra L Pegg; Leanne T Cooper; Jing Zhao; Michael Gerometta; Fiona M Smith; Michael Yeh; Perry F Bartlett; Jeffrey J Gorman; Andrew W Boyd
Journal:  Sci Rep       Date:  2017-07-26       Impact factor: 4.379

5.  Evidence that the EphA2 receptor exacerbates ischemic brain injury.

Authors:  John Thundyil; Silvia Manzanero; Dale Pavlovski; Tanya R Cully; Ker-Zhing Lok; Alexander Widiapradja; Prasad Chunduri; Dong-Gyu Jo; Chie Naruse; Masahide Asano; Bradley S Launikonis; Christopher G Sobey; Mark G Coulthard; Thiruma V Arumugam
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.